CDK4 and neoplasm: In a recent study, Shi and colleagues assessed the efficiency of another CDK4/6 inhibitor dalpiciclib in head and neck mucosal melanoma (HNMM) patients with CDK4 amplification using PDX mouse models and patient-derived tumor cells (PDCs) (Table 2) [22].